儿童和青少年RANKL介导疾病的狄诺塞麦管理:全球专家指导文件
本文为全球专家指导文件,由6个国家10名儿童骨与矿物质医学专家参与制定,总结狄诺塞麦用于儿童和青少年RANKL介导疾病的证据与专家意见。狄诺塞麦有效但常非治愈性,部分病例宜联合手术或其他药物治疗,需多学科规划并专家监督以管理矿物质异常风险,尚需协作研究确定最佳方案并减少风险。
要点
- 狄诺塞麦是儿童和青少年RANKL介导疾病的有效治疗,但常非治愈性。
- 部分病例宜与手术或其他药物治疗联合使用。
- 需仔细的多学科规划以确定治疗目标,并需专家监督以管理矿物质异常风险。
核心结论
- 狄诺塞麦是儿童和青少年RANKL介导疾病的有效治疗,但常非治愈性,部分病例最好与手术或其他药物治疗联合使用。
- 需要仔细的多学科规划来确定治疗目标,并需要专家监督以管理矿物质异常的风险。
- 需要进行实质性的协作研究以确定最佳治疗方案并尽量减少风险。
研究设计与样本
- 全球专家指导文件,由来自6个国家的10名具有狄诺塞麦使用经验的儿童骨与矿物质医学专家参与制定。
- 证据来源于已发表文献,主要为病例报告/系列和综述文章,因缺乏更高级别证据;无已发表数据时大量使用作者专家意见。
临床怎么用
- 作者认为狄诺塞麦是儿童和青少年RANKL介导疾病的有效治疗,但常非治愈性,部分病例最好与手术或其他药物治疗联合使用。
- 作者认为需要仔细的多学科规划来确定治疗目标,并需要专家监督以管理矿物质异常的风险。
局限性
- 证据主要来自病例报告/系列和综述文章,因缺乏更高级别证据。
- 无已发表数据时大量使用作者专家意见。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Denosumab is an effective treatment for many receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated disorders but there are potential safety considerations and limited data to guide its use in children and adolescents. OBJECTIVE: This document seeks to summarize the evidence and provide expert opinion on safe and appropriate use of denosumab in pediatric RANKL-mediated disorders. PARTICIPANTS: Ten experts in pediatric bone and mineral medicine from 6 countries with experience in the use of denosumab participated in the creation of this document. EVIDENCE: Data were sourced from the published literature, primarily consisting of case reports/series and review articles because of the lack of higher level evidence. Expert opinion of the authors was used substantially when no published data were available. CONCLUSION: Denosumab is an effective treatment for RANKL-mediated disorders in children and adolescents but is often not curative and, in some cases, is best used in conjunction with surgical or other medical treatments. Careful multidisciplinary planning is required to define the goals of treatment and expert oversight needed to manage the risk of mineral abnormalities. Substantive, collaborative research efforts are needed to determine optimal treatment regimens and minimize risks.
引用
- Vanderniet JA, Szymczuk V, Högler W, et al. Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document. J Clin Endocrinol Metab. 2024. PMID: 38041865. doi:10.1210/clinem/dgad657
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。